SIA "IS GROUP PHARMA"Active

40103724554Limited liability companyFounded 2013

Key figures

3 874 233 €+56,1%
Revenue 2025
+29,0%
Average annual growth 2014–2025
01 m2 m3 m4 m’14’15’16’17’18’19’20’21’22’23’24’25

Ratios

2025
Balance sheet structure
Current assetsNon-current assetsLiabilitiesEquity
01 m2 m’14’15’16’17’18’19’20’21’22’23’24’25

Dividends

calculated
2025

Paid out in dividends approximately 167 809 € (13% of equity at the end of the previous year).

Low confidence: the company does not file a cash flow statement, so the amount is an estimate from changes in equity — it may also include other reductions of equity (e.g. a share capital reduction).

History
2025 ~167 809 €
20240 €
20230 €
2022 ~169 999 €
2021 ~350 970 €
2020 ~14 245 €
2019 ~67 000 €
2018 ~217 298 €
20170 €
20160 €
20150 €
Summary of financial statements2014–2025
201420152016201720182019202020212022202320242025
Balance sheet — assets
Total current assets34 85223 895114 888291 515420 265748 9691 195 7671 099 6071 155 6981 229 6151 288 3921 595 846
Total non-current assets51 601100 13486 053151 908132 954158 337140 39563 96135 67295 968160 687131 974
Total assets86 453124 029200 941443 423553 219907 3061 336 1621 163 5681 191 3701 325 5831 449 0791 727 820
Balance sheet — liabilities and equity
Current liabilities2057678031 38153 12562 262128 137264 046159 695179 409124 591164 080112 488
Non-current liabilities000000000000
Total liabilities2057678031 38153 12562 262128 137264 046159 695179 409124 591164 080112 488
Share capital————————————
Retained earnings of previous periods————————————
Profit for the year439622 24952 311217 298317 957355 212307 192282 727178 087189 03184 007498 142
Total equity84 396117 249169 560390 298490 957779 1691 072 1161 003 8731 011 9611 200 9921 284 9991 615 332
Income statement
Sales revenue235 680265 338458 3551 772 628782 6541 962 1622 081 7932 894 3752 556 1662 918 0772 482 4743 874 233
Operating profit620224 16959 164267 616-876 984354 723307 192370 466220 668189 11679 643496 040
Profit before income tax618424 16959 066257 945317 957355 212307 192370 466220 668189 12284 133498 145
Profit for the reporting year439622 24952 311217 298317 957355 212307 192282 727178 087189 03184 007498 142
Labour costs————————————
Depreciation of non-current assets————————————
Other indicators
Employees235667689131310
Calculated dividend—000217 29867 00014 245350 970169 99900167 809

A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.

Connections graph

Click a node to see its other connections.

19,65%0,35%SIA "IS GROUP PHARMA"1Leitāns Jurijs
CompanyPersonShareholderOther roleAdditional link

Related companies

Companies in which this company is a member

Summary: SIA "IS GROUP PHARMA"

Overview

SIA "IS GROUP PHARMA" (reg. no. 40103724554) is a limited liability company. The company was registered in 2013 and has been in the register for 13 years. Registered address: Rīga, Ganību dambis 26A.

Financial results

Revenue in 2025 was 3 874 233 €, up 56,1% on the previous year (2 482 474 €). From 2014 to 2025, revenue grew by an average of 29,0% per year. This is the company's highest revenue among the published years (2014–2025). Net profit for 2025 was 498 142 € (12,9% of revenue). The company was profitable in all 12 published years. In 2025 the company had 10 employees (13 a year earlier). Revenue per employee was 387 423 €. At the end of 2025, total assets were 1 727 820 € and equity 1 615 332 € (93,5% of assets).

Management and owners

The company has one board member. According to the register, the company has 2 owners. The largest stake (19,7%) is held by SIA "IS GROUP PHARMA". The company holds a stake in one other active Latvian company.

Data sources and freshness

Register data (name, address, legal form, board and owners) and annual report figures come from the open data of the Register of Enterprises of the Republic of Latvia (CC0); entity.lv updates them daily. Data as of 02.11.2026. Changes, averages and ratios are calculated by entity.lv from open data and are not an official assessment.